克利加巴林

克利加巴林
臨床資料
商品名（英語：Drug nomenclature）	思美寧
其他名稱	HSK16149
法律規範狀態
法律規範	中：處方藥 ; 美：研究性新藥（英語：Investigational New Drug）;
識別資訊
CAS號	2209104-84-5
UNII	Q3MK7E8686;
化學資訊
化學式	C12H19NO2
摩爾質量	209.29 g·mol−1

克利加巴林（英語：Crisugabalin，研發代號：HSK16149），商品名思美寧，是一種選擇性GABA類似物，正在開發用於治療慢性疼痛。它的治療指數比作用機制相似的普瑞巴林更廣。該藥物由海思科醫藥集團研發，於2024年5月在中國大陸獲批用於治療糖尿病性周圍神經病理性疼痛^[2]^[3]，7月獲批第二個適應症帶狀疱疹後神經痛（英語：Postherpetic neuralgia）^[4]。在美國，該藥物已於2023年進入III期臨床試驗階段^[5]^[6]。該藥物可與食物同服或空腹服用^[7]。

克利加巴林的作用機制尚不明確^[1]。

參見

研究性鎮痛藥列表（英語：List of investigational analgesics）

參考來源

^ ^1.0 ^1.1 ^1.2 思美宁（苯磺酸克利加巴林胶囊）. 丁香園·用藥助手. [2025-04-26].
^ Monthly Report: New Drug Approval in China, May 2024. [2025-04-26]. （原始內容存檔於2024-12-09）.
^ 国家药监局批准苯磺酸克利加巴林胶囊上市. 國家藥品監督管理局. 2024-05-20 [2025-04-26].
^ 海思科苯磺酸克利加巴林胶囊获批新适应症. 中國醫藥創新促進會. 2024-07-19 [2025-04-26].
^ Gou, Xiaoli; Yu, Xiaojuan; Bai, Dongdong; Tan, Bowei; Cao, Pingfeng; Qian, Meilin; Zheng, Xiaoxiao; Chen, Lei; Shi, Zongjun; Li, Yao; Ye, Fei; Liang, Yong; Ni, Jia. Pharmacology and Mechanism of Action of HSK16149, a Selective Ligand of α2δ Subunit of Voltage-Gated Calcium Channel with Analgesic Activity in Animal Models of Chronic Pain. The Journal of Pharmacology and Experimental Therapeutics. 2021-03, 376 (3): 330–337. ISSN 1521-0103. PMID 33293377. doi:10.1124/jpet.120.000315 .
^ Guo, Xiaohui; Zhang, Tingting; Yuan, Geheng; Yukun, LI; Hua Ma, Jian; Hong-Mei, LI. 224-OR: The Efficacy and Safety of HSK 16149 in Chinese with Diabetic Peripheral Neuropathic Pain—A Randomized, Double-Blinded, Placebo and Pregabalin-Controlled Phase II/III Study. Diabetes. 2023, 72. doi:10.2337/db23-224-OR.
^ Wu, Qingqing; Zhu, Huijuan; Song, Rong; Zhang, Mengqi; Li, Fangqiong; Zeng, Weifang; Wang, Wei; Jia, Jingying; Yu, Chen; Liu, Yanmei. Effect of a high-fat and high-calorie food on the pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy subjects. Pharmacology Research & Perspectives. 2023-06, 11 (3): e01102. PMC 10199234 . PMID 37208866. doi:10.1002/prp2.1102 .

這是一篇與藥學相關的小作品。您可以透過編輯或修訂擴充其內容。

[dxy-1] 1.0 ^1.1 ^1.2 思美宁（苯磺酸克利加巴林胶囊）. 丁香園·用藥助手. [2025-04-26].

[2] Monthly Report: New Drug Approval in China, May 2024. [2025-04-26]. （原始內容存檔於2024-12-09）.

[3] 国家药监局批准苯磺酸克利加巴林胶囊上市. 國家藥品監督管理局. 2024-05-20 [2025-04-26].

[4] 海思科苯磺酸克利加巴林胶囊获批新适应症. 中國醫藥創新促進會. 2024-07-19 [2025-04-26].

[5] Gou, Xiaoli; Yu, Xiaojuan; Bai, Dongdong; Tan, Bowei; Cao, Pingfeng; Qian, Meilin; Zheng, Xiaoxiao; Chen, Lei; Shi, Zongjun; Li, Yao; Ye, Fei; Liang, Yong; Ni, Jia. Pharmacology and Mechanism of Action of HSK16149, a Selective Ligand of α2δ Subunit of Voltage-Gated Calcium Channel with Analgesic Activity in Animal Models of Chronic Pain. The Journal of Pharmacology and Experimental Therapeutics. 2021-03, 376 (3): 330–337. ISSN 1521-0103. PMID 33293377. doi:10.1124/jpet.120.000315 .

[6] Guo, Xiaohui; Zhang, Tingting; Yuan, Geheng; Yukun, LI; Hua Ma, Jian; Hong-Mei, LI. 224-OR: The Efficacy and Safety of HSK 16149 in Chinese with Diabetic Peripheral Neuropathic Pain—A Randomized, Double-Blinded, Placebo and Pregabalin-Controlled Phase II/III Study. Diabetes. 2023, 72. doi:10.2337/db23-224-OR.

[7] Wu, Qingqing; Zhu, Huijuan; Song, Rong; Zhang, Mengqi; Li, Fangqiong; Zeng, Weifang; Wang, Wei; Jia, Jingying; Yu, Chen; Liu, Yanmei. Effect of a high-fat and high-calorie food on the pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy subjects. Pharmacology Research & Perspectives. 2023-06, 11 (3): e01102. PMC 10199234 . PMID 37208866. doi:10.1002/prp2.1102 .

[1]

[2]

[3]

[4]

[5]

[6]

[7]